Patent ID: 8642278

Claim:
A method of inhibiting proliferation of a cell, comprising contacting the cell with an effective amount of a compound represented by structural formula Ia: or a pharmaceutically acceptable salt thereof, wherein: Ring A is optionally substituted, and zero, one, or two of the ring atoms in Ring A are N; and Ring A is fused with zero, one, or two optionally substituted 3-15 membered monocyclic or polycyclic rings selected from the group consisting of aryl, heteroaryl, heterocyclyl, and cycloaliphatic; Y is an optionally substituted C 1-3 alkylene or C 1-3 alkenylene; X 2 is optionally substituted ═NH; X 3 is optionally substituted —NH 2 , each substitutable carbon is optionally substituted with a carbon substituent independently selected from the group consisting of —F, —Cl, —Br, —I, —CN,—NO 2 , —R a , —OR a , —C(O)R a , —OC(O)R a , —C(O)OR a , —SR a , —C(S)R a , —OC(S)R a , —C(S)OR a , —C(O)SR a , —C(S)SR a , —S(O)R a , —SO 2 R a , —SO 3 R a , —OSO 2 R a , —OSO a R a , —PO 2 R a R b , —OPO 2 R a R b , —PO 3 R a R b , OPO 3 R a R b , —N(R a R b ), —C(O)N(R a R b ), —C(O)NR a NR b SO 2 R c , —C(O)NR a SO 2 R c , —C(O)NR a CN, —SO 2 N(R a R b ), —NR a SO 2 R b , —NR c C(O)R a , —NR c C(O)OR a , NR c C(O)N(R a R b ), —C(NR c )—N(R a R b ), —NR d —C(NR c )—N(R a R b ), —NR a N(R a R b ), —CR c ═CR a R b , —C≡CR a , ═O, ═S, ═CR a R b , ═NR a , ═NOR a , and ═NNR a , or two substitutable carbons are linked with C 1-3 alkylenedioxy; each substitutable nitrogen is: optionally substituted with a nitrogen substituent independently selected from the group consisting of —CN, —NO 2 , —R a , —OR a , —C(O)R a , —C(O)R a —aryl, —OC(O)R a , —C(O)OR a , —SR a , —S(O)R a , —SO 2 R a , —SO 3 R a , —N(R a R b ), —C(O)N(R a R b ), —C(O)NR a NR b SO 2 R c , —C(O)NR a SO 2 R c , —C(O)NR a CN, —SO 2 N(R a R b ), —NR a SO 2 R b , —NR c C(O)R a , —NR c C(O)OR a , —NR c C(O)N(R a R b ), and oxygen toform an N-oxide; and optionally protonated or quaternary substituted to carry a positive charge which is balanced by a pharmaceutically acceptable counterion; wherein each R a —R d is independently —H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 aralkyl, aryl, heteroaryl, heterocyclyl, or cycloaliphatic, or, —N(R a R b ), taken together, is an optionally substituted heterocyclic group; X 2 , X 3 , each nitrogen substitutent, and each carbon substituent is optionally protected with a protecting group; and provided the compound is not benzyl N,N′-bis(tert-butoxy carbonyloxy)carbamimidothioate or a salt represented by